Physician profile
Baldev K Singh
NPI 1760559959
$2,726.01
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $187 · 2021: $257 · 2022: $610 · 2023: $339 · 2024: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $501.58 | 2020-2024 | Fycompa |
| Teva Pharmaceuticals USA, INC. | $456.79 | 2019-2020 | |
| Genentech USA, INC. | $273.38 | 2019 | |
| Amneal Pharmaceuticals LLC | $249.48 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $226.44 | 2022-2024 | Epidiolex |
| Eisai INC. | $174.88 | 2021-2023 | |
| Greenwich Biosciences, INC. | $152.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $125.00 | 2019 | |
| Ucb, INC. | $104.61 | 2022-2023 | Fintepla |
| Neurelis, INC. | $93.70 | 2022 | |
| Argenx US, INC. | $85.82 | 2023 | Vyvgart |
| Sk Life Science, INC. | $45.22 | 2022 | |
| Zimmer Biomet Holdings, INC. | $36.22 | 2022 | |
| Monteris Medical Corporation | $34.06 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $34.06 | 2022 | |
| Sumitomo Pharma America, INC. | $7.00 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baldev Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.